Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21822831 | 0.90 | NPSR1 (0.39) | NPSR1PKM | |
| SCHEMBL12503609 | 0.88 | NPSR1 (0.42) | NPSR1 | |
| SCHEMBL27915505 | 0.78 | NPSR1 (0.34) | NPSR1 | |
| SCHEMBL7971343 | 0.76 | CA1 (0.30) | — | |
| SCHEMBL15428502 | 0.76 | NPSR1 (0.33) | NPSR1 | |
| SCHEMBL3309990 | 0.76 | BLM (0.30) | KDM4E | |
| SCHEMBL18756627 | 0.73 | DGAT1 (0.39) | NPSR1 | |
| SCHEMBL26910776 | 0.73 | SPHK1 (0.31) | — | |
| Hydrochloric Acid SCHEMBL18725618 | 0.72 | DGAT1 (0.38) | NPSR1 | |
| SCHEMBL20447427 | 0.70 | NPSR1 (0.59) | NPSR1PKMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3774750-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | Betta Pharmaceuticals Co., Ltd (CN) | 2021-02-17 | — | — | EP | claimed |
| US-20200360387-A1 | CYCLOALKYL SUBSTITUTED PYRAZOLOPYRIMIDINES HAVING ACTIVITY AGAINST RSV | JANSSEN-CILAG (FR) | 2020-11-19 | — | — | US | claimed |
| WO-2019192506-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2019-10-10 | — | — | WO | claimed |
| US-12617783-B2 | Heterocyclic GLP-1R agonists | BIOMEA FUSION, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20250304572-A1 | HETEROCYCLIC GLP-1R AGONISTS | BIOMEA FUSION, INC. | 2025-10-02 | — | — | US | disclosed |
| EP-3807254-A1 | HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE | Epigen Biosciences, Inc. (US) | 2021-04-21 | — | — | EP | disclosed |
| EP-3774750-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | Betta Pharmaceuticals Co., Ltd (CN) | 2021-02-17 | — | — | EP | disclosed |
| CN-110785408-A | Modulators of indoleamine2, 3-dioxygenase | 葛兰素史克知识产权开发有限公司 | 2020-02-11 | — | — | CN | disclosed |
| WO-2019192506-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2019-10-10 | — | — | WO | disclosed |
| EP-2970155-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE (IDO) | Bristol-Myers Squibb Company (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014150677-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE (IDO) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2008072077-A2 | COMBINATION OF 1-ARYL-4-CYCLOPROPYLPYRAZOLES WITH ANTHELMINTIC AGENT FOR PARASITIC INFESTATION | PFIZER LIMITED (GB) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304572-A1 | HETEROCYCLIC GLP-1R AGONISTS | GLP1R, GPR119, GIPR | NPSR1 268/4885PKM 2709/4885KDM4E 3920/4885 |
| US-20200360387-A1 | CYCLOALKYL SUBSTITUTED PYRAZOLOPYRIMIDINES HAVING ACTIVITY AGAINST RSV | ACE, ACE2, PTBP1 | NPSR1 3124/4885PKM 575/4885KDM4E 2742/4885 |
| US-12617783-B2 | Heterocyclic GLP-1R agonists | GLP1R, GIPR, GPR119 | NPSR1 485/4885PKM 3810/4885KDM4E 2335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.